GBP510
GBP510 je kandidát na vakcínu proti nemoci COVID-19 vyvinutý společnostmi SK Bioscience a GSK.[1][2][3][4][5] Vakcína byla vyvinute ve spolupráci s Institutem pro proteinový design Washingtonské univerzity.[6][7]
Jihokorejské ministerstvo pro bezpečnost potravin a léčiv zahájilo v srpnu 2021 klinickou studii fáze III, do které se zapojilo odhadem 3990 účastníků.[8][9][10]
Odkazy
[editovat | editovat zdroj]Reference
[editovat | editovat zdroj]V tomto článku byl použit překlad textu z článku GBP510 na anglické Wikipedii.
- ↑ SK bioscience. www.skbioscience.co.kr [online]. [cit. 2021-11-16]. Dostupné online.
- ↑ CEPI and SK bioscience extend collaboration to develop ‘next generation’ COVID-19 vaccine. CEPI [online]. [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ SK BIOSCIENCE CO., LTD. A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults. [s.l.]: [s.n.] Dostupné online. Submitted: February 10, 2021.
- ↑ SK BIOSCIENCE CO., LTD. A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults. [s.l.]: [s.n.] Dostupné online. Submitted: February 4, 2021.
- ↑ SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington. Businesskorea [online]. 2021-06-11 [cit. 2021-11-16]. Dostupné online. (korejsky)
- ↑ Two nanoparticle vaccines enter clinical trials – Institute for Protein Design [online]. [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine. newsroom.uw.edu [online]. 2021-05-24 [cit. 2021-11-16]. Dostupné online.
- ↑ SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing. www.bioworld.com [online]. [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial. Businesskorea [online]. 2021-08-31 [cit. 2021-11-16]. Dostupné online. (korejsky)
- ↑ SK BIOSCIENCE CO., LTD. A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older. [s.l.]: [s.n.] Dostupné online. Submitted: August 9, 2021.